Rana Al-Hallaq

Rana Al-Hallaq has been involved in a variety of roles throughout their career. In 2021, they were appointed Director Board of Directors at Triplet Therapeutics, Observer Board of Directors at Jnana Therapeutics, Director Board of Directors at ReCode Therapeutics, Vivet Therapeutics and RefleXion Medical. In 2020, they were appointed Director Board of Directors at Montis Biosciences. In 2019, they were appointed Observer Board of Directors at Arkuda Therapeutics, Director Board of Directors at NY BIO and Autifony Therapeutics. Prior to this, they held various roles at Pfizer from 2015, including Partner, Pfizer Ventures and Executive Director, Pfizer Worldwide Business Development, Senior Director and Partner, Pfizer Ventures, Senior Director and Principal, Pfizer Ventures, Director Business Development and Early Candidate Clinical Lead.

Rana Al-Hallaq obtained a BA in Biology from Hamilton College between 1992 and 1996. Rana then went on to pursue a PhD in Neuroscience from Georgetown University, which they completed in 2002.